Insects (whole body), mite dermatophagoides farinae - Biologic Drug Details

Summary for insects (whole body), mite dermatophagoides farinae

Tradenames:	1
High Confidence Patents:	0
Applicants:	5
BLAs:	5
Suppliers: see list	4

Pharmacology for insects (whole body), mite dermatophagoides farinae

Physiological Effect	Cell-mediated Immunity Increased Histamine Release Increased IgG Production
Established Pharmacologic Class	Standardized Insect Allergenic Extract
Chemical Structure	Allergens Antigens, Dermatophagoides Insect Proteins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for insects (whole body), mite dermatophagoides farinae Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for insects (whole body), mite dermatophagoides farinae Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for insects (whole body), mite dermatophagoides farinae Derived from Patent Text Search

No patents found based on company disclosures

Insects (whole body), mite dermatophagoides farinae Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Biologic Drugs: Focus on Dermatophagoides farinae

Introduction

The biologics market is experiencing significant growth, driven by various factors including the increasing prevalence of chronic diseases, advancements in drug delivery systems, and the rising adoption of biosimilars. One of the biologic drugs gaining attention is the extract from the American house dust mite, Dermatophagoides farinae, used primarily for immunotherapy against house dust mite-induced allergic rhinitis and asthma.

Biologics Market Overview

The global biologics market is projected to reach USD 699.5 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 7.8% from 2024 to 2032. This growth is fueled by the increasing incidence of chronic diseases, technological advancements, and the strong pipeline of biologic drugs[1].

Drivers of the Biologics Market

Several key factors are driving the growth of the biologics market:

Increasing Burden of Chronic Diseases

The rising prevalence of chronic diseases such as allergies, autoimmune disorders, and cancer is a significant driver. Biologic therapies offer targeted and often more effective treatments for these conditions[1].

Technological Advancements

Continuous advancements in biotechnology and drug delivery systems are enhancing the efficacy and safety of biologic drugs. This includes the development of more targeted therapies and improved manufacturing processes[1].

Growing Adoption of Biosimilars

Biosimilars, which are biologic drugs that are highly similar to an already approved biologic drug, are gaining traction due to their cost-effectiveness and similar efficacy profiles. This segment is expected to grow significantly, contributing to the overall market growth[4].

Dermatophagoides farinae: A Specific Biologic Drug

Indications and Use

Dermatophagoides farinae extracts are used as immunotherapy for house dust mite-induced allergic rhinitis and conjunctivitis. These extracts are available in various forms, including sublingual tablets and subcutaneous injections, and are approved for patients aged 12 to 65 years[2].

Market Impact

The demand for Dermatophagoides farinae extracts is increasing due to the high prevalence of dust mite allergies. This demand is part of the broader trend of growing interest in biologic therapies for allergic conditions.

Financial Trajectory

Current Market Value

The biologics market, which includes drugs like Dermatophagoides farinae, was valued at USD 349.6 billion in 2023. This value is expected to more than double by 2032, reaching USD 699.5 billion[1].

Growth Rate

The biologics market is anticipated to grow at a CAGR of 7.8% from 2024 to 2032. This growth rate is influenced by the increasing adoption of biologic therapies across various therapeutic areas, including allergy treatments[1].

Segmental Growth

The monoclonal antibody segment, which is a significant part of the biologics market, is expected to dominate the market throughout the forecast period. However, other segments, including allergenics like Dermatophagoides farinae, are also expected to contribute substantially to the overall growth[4].

Regional Market Dynamics

North America

North America accounted for a substantial value share of 43.8% in the biologics market in 2023. This region is expected to continue its dominance due to advanced healthcare infrastructure and high awareness about biologic therapies[4].

Asia-Pacific

Countries like China and India are expected to exhibit high growth rates, with China's biosimilar and biologics market projected to grow at a CAGR of 8.8% and India at 8.5% from 2024 to 2034. This growth is driven by increasing healthcare access and a rising incidence of chronic diseases[4].

Production and Quality Assurance

Manufacturing Process

The production of Dermatophagoides farinae extracts involves physical separation methods to isolate the mites from the growth medium. This process ensures minimal contamination and preserves the native proteins of the mites, which is crucial for the efficacy of the allergen extracts[5].

Quality Assurance

Manufacturers like Citeq Biologics provide detailed certificates of analysis for their products, including information on allergenic patterns, protein content, endotoxin levels, and protease activity. This emphasis on quality assurance is critical for maintaining the trust of researchers and healthcare providers[5].

Future Outlook

Increasing Demand for Allergy Treatments

The demand for biologic treatments for allergies, including those caused by house dust mites, is expected to rise. This is due to the growing awareness of allergy treatments and the increasing prevalence of allergic conditions.

Technological Innovations

Advancements in biotechnology and drug delivery systems will continue to enhance the efficacy and safety of biologic drugs like Dermatophagoides farinae. These innovations will also make these treatments more accessible and affordable.

Regulatory Approvals

The escalating approvals of biologics by regulatory agencies will further boost the market. As more biologic drugs receive approval, the market is expected to expand, driven by the increasing availability of these therapies[1].

Key Takeaways

• The biologics market is projected to reach USD 699.5 billion by 2032, growing at a CAGR of 7.8%.
• Dermatophagoides farinae extracts are a significant part of this market, used for immunotherapy against house dust mite-induced allergies.
• The market is driven by the increasing prevalence of chronic diseases, technological advancements, and the growing adoption of biosimilars.
• North America and Asia-Pacific regions are expected to be key markets, with high growth rates anticipated in countries like China and India.
• Quality assurance and technological innovations are crucial for the continued growth and acceptance of biologic drugs.

FAQs

What is the projected growth rate of the biologics market from 2024 to 2032?

The biologics market is expected to grow at a CAGR of 7.8% from 2024 to 2032[1].

What are the primary drivers of the biologics market?

The primary drivers include the increasing prevalence of chronic diseases, technological advancements, and the growing adoption of biosimilars[1].

What is the indication for Dermatophagoides farinae extracts?

Dermatophagoides farinae extracts are indicated for immunotherapy against house dust mite-induced allergic rhinitis and conjunctivitis[2].

How are Dermatophagoides farinae extracts produced?

The extracts are produced by physically separating the living mites from the growth medium, ensuring minimal contamination and preserving native proteins[5].

Which regions are expected to dominate the biologics market in the future?

North America is expected to continue its dominance, while Asia-Pacific regions, particularly China and India, are anticipated to exhibit high growth rates[4].

Sources

1. Biologics Market Size to Reach USD 699.5 Billion by 2032, Impelled by Emergence of Advanced Drug Delivery Systems. Biospace.
2. Dermatophagoides farinae: Uses, Interactions, Mechanism of Action. DrugBank.
3. Population growth of Dermatophagoides farinae Hughes (Acari: Pyroglyphidae) in the presence of insect growth regulators. PubMed.
4. Biosimilar and Biologics Market Is Expected to Reach USD 1,060.7 Billion by 2034. GlobeNewswire.
5. Dermatophagoides farinae mite bodies. Citeq Biologics.